IICN Registrar’s Neuroscience 2010 Four Seasons Hotel, Dublin November 5th 2010 RESEARCH PRESENTATIONS (12 mins: 10 mins presentation + 2 mins Qs)
10.40 Familial ALS: Defining the true rate of familial ALS, assessing the role of chance occurrence within kindreds, and proposing criteria for familial ALS. Susan Byrne1,2, Cathal Walsh1, Catherine Lynch2, Orla Hardiman1,2 10.52 Significance of anti-skeletal muscle antibodies in autoimmune myasthenia gravis. Carr AS1,2, Cardwell C2, McCarron Peter2, McConville J1, 3. 11.04 The Kurtzke EDSS rank stability increases 4 years after onset of Multiple Sclerosis: results from the MSBase Registry. Hughes SE1, Gray OM2, Butzkueven H3, on behalf of the MSBase Registry3.
11.16 Natalizumab: what happens when we stop it?
SB Kelly, M Duggan, K Kinsella, C McGuigan, N Tubridy, M Hutchinson
11.28 Prevalence of ex vivo non-responsiveness to commonly prescribed antiplatelet therapy following TIA or ischaemic stroke: results from the TRinity AntiPlatelet responsiveness (TRAP) study Tobin WO1, Kinsella JA1, Collins DR2,3, Coughlan T2,3, O’Neill D2,3, Egan B4, Tierney S4, Feeley TM4, Murphy RP1,3, McCabe DJH1,3,5
11.40 Gamma-aminobutyric acid transporter 1 (GAT-1) expressing synaptic inputs in the lateral amygdala of pharmacoresistant temporal lobe epilepsy patients Ayman Khalil, Don O`Leary , Albert Becker , Johannes Schramm , Deniz M. Yilmazer-Hanke 11.52 Independent association of carotid stenosis with very early stroke recurrence causing long-term disability in the North Dublin Population Stroke Study Michael Marnane MB MRCPI, Danielle Ni Chroinin MB MRCPI, Elizabeth Callaly MB MRCPI, Orla C Sheehan MB MRCPI, Aine Merwick MB MRCPI, Niamh Hannon MB MRCPI, Gillian Horgan BSc, Lorraine Kyne MD MPH FRCPI, Joan Moroney MD MRCPI, Patricia ME McCormack MD FRCPI DCH, Eamon Dolan MD, Joseph Duggan MD FRCPI, David Williams PhD FRCPI, Gloria Crispino-O’Connell PhD, Peter J Kelly MD MS FRCPI 12.04 Addition of brain and carotid imaging to the ABCD2 score to improve identification of patients at high early stroke risk after transient ischaemic attack.
Merwick Á1, Albers GW2, Amarenco P3, Arsava EM4, Ay H4, Calvet D5, Coutts SB6, Cucchiara BL7, Demchuk AM6, Furie KL4, Giles M8, Labreuche J3, Lavallée P3, Mas JL5, Olivot JM2, Purroy F9, Rothwell PM 8, Saver JL10, Sheehan ÓC1, Stack JP1, Walsh C11, Kelly PJ1.
12.16 Laboratory non-responsiveness to commonly prescribed antiplatelet regimens under low and high stress conditions following TIA or ischaemic stroke: results from the TRinity AntiPlatelet responsiveness (TRAP) study Justin A Kinsella MRCPI*, W Oliver Tobin MRCPI*, Dermot Cox PhD†, Tara Coughlan MRCP∞, Ronan Collins MD∞, Desmond O’Neill MD,
Raymond P Murphy FRCPI*∞, Dominick J H McCabe PhD, FRCPI*∞‡
12.28 Synaptic input to neuropeptide y (npy) immunoreactive neurones in the amygdala of pharmacoresistant temporal lobe epilepsy patients
Uchenna Okafo1, Don O`Leary2, Ayman Khalil3, Albert Becker4, Johannes Schramm5, Deniz Yilmazer-Hanke6.
12.40 The prevalence of Nonconvulsive Seizures in PICU: a prospective clinical- video EEG study. Dr. Declan O’Rourke, Prof. Mary King, Dr. Amre Shahwan 13.00 Lunch CASE PRESENTATIONS (10 mins: 8 mins presentation + 2 mins Qs)
14.10Severe sensory axonal neuropathy secondary to primary amyloidosis associated with a MGUS. Cummins G1. Hardiman O2, Ruttledge M3.
14.20 Painful generalised dysaesthesia, palatal myoclonus, bilateral inferior olivary hypertrophy and a unilateral brain stem lesion. 14.30 Brain metastasis from prostate carcinoma
Ayman Khalil, Chandrasekaran Kaliaperumal, Eoin Fenton, Uchenna Okafo Catherine Keohane, Charles Marks
14.40 Turn Out The Lights: a case report
A. Laffan, M. Healion, A. Sweeney, C. Doherty, Y. Langan
14.50 Cerebral Vasculitis Mimicking FTD with Parkinsonism.
Dr. Allan Mc Carthy1, Dr. Donal Costigan2, Prof Michael Farrell3, Dr. Killian O’Rourke4, Prof Timothy Lynch5
15.00 The Elephant in the Brainstem 15.20 – 15.40 Tea / Coffee break 15.40 Lewy Body Disease Presenting with Clinical Features of Frontotemporal Dementia: a Case Series O’Dowd S1, Kearney H1, Murray B1, Doherty C2, Farrell M3, Keohane C4, Lynch T1 15.50 Stiff person syndrome (SPS) complicated by respiratory failure: successful treatment with rituximab. ANAS QURESHI, MICHAEL HENNESSY.
16.00Neurosarcoidosis-related intracranial hemorrhage: three new cases and systematic review of the literature O'Dwyer JP MRCPI (1), Al-Moyeed BA MB (2), Farrell MA FRCPath (3) Pidgeon CN FRCSI (4), Collins DR MD (5), Fahy A FFARCSI (6), Dempsey O FRCP (7), Kidd DP FRCP (8), Reid JM FRCP (2), Smyth S MRCPI (1), McCabe DJH PhD, FRCPI (1,8).
16.10 A rare cause of adult onset ataxia and palatal temor
Dr Kinley Roberts, Dr Killian O’Rourke, Professor Tim Lynch
16.20 Abdominal wall endometrioma in a patient with lumbo-peritoneal shunt: case report Shoakazemi A1, Brady A2, Cooke RS3
16.30 All That Glisters is Not Gold
Tobin WO1, Jansen M2, O’Connell K1, Gaughan M1, Molnar PP2, Hutchinson
16.40 A little Botox can go a long way.
D. Bradley1, S. Connolly2, M. Farrell3, M. King4, K. Bhatia5, M. Hutchinson1.
17.10 Announcement and presentation of Prizes
INALAÇÃO DE OXIGÉNIO EM MEIO HIPERBÁRICO:FUNDAMENTOS DA SUA UTILIZAÇÃO NO TRATAMENTO DO PÉ DIABÉTICODiplomado em Medicina Hiperbárica e Subaquática pela Universidade de Lílle - França. Centro de Medicina Hiperbárica do Hospital da Marinha. RESUMOA oxigenoterapia hiperbárica (HBOT) baseia-se na inalação de oxigênio puro a uma pressão ambiente superior àpressão atmosférica,
ED I T O R I A LS “Those who cannot remember the past are condemnedhence Viagra and Zyprexa), was launched in 2001 to the samehype and with even more sophisticated marketing tech“Scepticism is the chastity of the intellect, and it isBy late 2005, it had recorded sales of $214.6 mspitethe release of a negative second studynd about $100 million despite growing concerns about its efficacy